PROCEPT BioRobotics Corporation $PRCT Stock Holdings Lifted by Eventide Asset Management LLC

Eventide Asset Management LLC increased its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 33.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 468,476 shares of the company’s stock after acquiring an additional 116,514 shares during the quarter. Eventide Asset Management LLC’s holdings in PROCEPT BioRobotics were worth $26,984,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BI Asset Management Fondsmaeglerselskab A S purchased a new position in PROCEPT BioRobotics during the 1st quarter worth approximately $40,000. Vega Investment Solutions grew its holdings in shares of PROCEPT BioRobotics by 52.0% during the second quarter. Vega Investment Solutions now owns 775 shares of the company’s stock valued at $45,000 after buying an additional 265 shares in the last quarter. AlphaQuest LLC grew its holdings in shares of PROCEPT BioRobotics by 1,262.5% during the second quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock valued at $63,000 after buying an additional 1,010 shares in the last quarter. CWM LLC raised its position in PROCEPT BioRobotics by 40.7% during the second quarter. CWM LLC now owns 1,228 shares of the company’s stock valued at $71,000 after buying an additional 355 shares during the period. Finally, RiverPark Advisors LLC lifted its stake in PROCEPT BioRobotics by 22.5% in the 2nd quarter. RiverPark Advisors LLC now owns 1,761 shares of the company’s stock worth $101,000 after acquiring an additional 324 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Performance

Shares of PRCT opened at $35.99 on Friday. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -23.52 and a beta of 0.99. The company’s fifty day moving average is $33.01 and its 200-day moving average is $43.59. The company has a quick ratio of 7.20, a current ratio of 8.44 and a debt-to-equity ratio of 0.14. PROCEPT BioRobotics Corporation has a 12 month low of $27.80 and a 12 month high of $92.92.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.03. The business had revenue of $83.33 million during the quarter, compared to analyst estimates of $80.78 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. PROCEPT BioRobotics’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.40) EPS. Equities analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

PRCT has been the topic of several research analyst reports. Wall Street Zen raised PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Morgan Stanley lowered their price objective on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 2nd. Wells Fargo & Company cut their target price on shares of PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Leerink Partners restated an “outperform” rating and set a $55.00 price target on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Finally, Jefferies Financial Group raised shares of PROCEPT BioRobotics to a “buy” rating in a research note on Friday. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, PROCEPT BioRobotics currently has an average rating of “Moderate Buy” and a consensus price target of $53.70.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).